REGENXBIO Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Operational Highlights

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. ACN
3. IBM
4. MU
5. PRIM
6. DPZ
7. NAVN
8. NVDA
9. DFTX
10. META

Go back to REGENXBIO Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Operational Highlights

Regenxbio (RGNX) Tops Q4 EPS by $1.96

March 1, 2022 4:36 PM EST

Regenxbio (NASDAQ: RGNX) reported Q4 EPS of $6.67, $1.96 better than the analyst estimate of $4.71. Revenue for the quarter came in at $398.7 million versus the consensus estimate of $271.74 million.

Based on its current operating plan, REGENXBIO expects its balance in cash, cash equivalents and marketable... More